Tru

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 0 5 2008

APPLICANT: Zang et al.

FILED: July 2, 2003

SERIAL NO.: 10/612,468

FOR: T Cell Receptor CDR3 Sequence

and Methods for Detecting and

Treating Rheumatoid Arthritis

๛๛๛๛๛๛๛๛

ART UNIT: 1644

EXAMINER:

Juedes, A.E.

DOCKET:

D6622

MAIL STOP SEQUENCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

ATTN: Examiner Amy E. Juedes

RESPONSE TO OFFICE COMMUNICATION AND CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

Dear Sir:

In response to an Office Communication, mailed November 4, 2008, please enter the following amendment and consider the following remarks.

I hereby certify under 37 CFR 1.8 that the following correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to MAIL STOP SEQUENCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

- 1) Response to Office Communication (3 pgs);
- 2) Sequence Listing (50 pgs), Sequence Compliance Statement (1 pg) & CRF; and
- 3) Copy of Notice to Comply.

Respectfully submitted,

ADLER & ASSOCIATES

8011 Candle Lane Houston, Texas 77071

Date:

Tel: (713) 270-5391 Fax: (713) 270-5361

Ben@adlerandassociates.com

Benjamin Aaron Adler, Ph.D., J.D.

Registration No. 35,423 Counsel for Applicant